J 2024

Newborn Hearing Screening - An Implementation Analysis

KOSTLIVY, Tomas, Petr SKOPEK, Pavel KLAIL, Hana LAIEROVA, Alena SKALOVA et. al.

Basic information

Original name

Newborn Hearing Screening - An Implementation Analysis

Authors

KOSTLIVY, Tomas (203 Czech Republic), Petr SKOPEK (203 Czech Republic), Pavel KLAIL (203 Czech Republic), Hana LAIEROVA (203 Czech Republic), Alena SKALOVA (203 Czech Republic), Břetislav GÁL (203 Czech Republic, belonging to the institution), Radek KUCERA (203 Czech Republic), Vaclav SIMANEK (203 Czech Republic) and David SLOUKA (203 Czech Republic)

Edition

In vivo, ATHENS, Greece : International Institute of Anticancer Research, 2024, 0258-851X

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30206 Otorhinolaryngology

Country of publisher

Greece

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

URL

Impact factor

Impact factor: 2.300 in 2022

Organization unit

Faculty of Medicine

DOI

http://dx.doi.org/10.21873/invivo.13650

UT WoS

001266321000049

Keywords in English

Newborn; hearing screening; hearing loss treatment

Tags

14110126, rivok

Tags

International impact, Reviewed
Změněno: 15/8/2024 10:22, Mgr. Tereza Miškechová

Abstract

V originále

Background/Aim: Hearing impairment affects a small but significant percentage of newborns (0.1-0.4%). Newborn hearing screening (NHS) is recommended for early detection and treatment. The implementation of NHS can vary among countries. In this study, we present the methodology, organization, and technical requirements of NHS. This study analyzed results from a tertiary hospital, identified issues, and proposed solutions. Patients and Methods: In the studied region, there are five maternity hospitals and a perinatal intensive care center and in 2020, there were 5,864 live births. Screening is performed at three levels. The first screening is conducted on the 2nd-3rd day of a newborn's life in a maternity hospital, the first rescreening on the 3rd-6th week at a relevant ENT department, and the second rescreening on the 3rd-6th month of life at the regional screening center where the central database is also held. Results: In the studied region, 5,793 out of 5,864 (98.79%) newborns received NHS in 2020. Of these, 120 (2.07%) were tested positive on their first screening. Ninetyfour patients (78.3%) of those attended the ENT department for a first rescreening. Thirty-four patients (0.59% of total) were tested positive again and referred to the regional screening center. Out of the 27 patients who attended the second rescreening, four (0.07% of the total) were ultimately diagnosed with hearing impairment. Conclusion: Our study found that newborn hearing screening (NHS) in our region achieved a high compliance rate of 98.8% for initial screenings in 2020. However, challenges remain in the rescreening process due to data management issues, interregional cooperation, and public awareness. The recent implementation of mandatory screenings, updated guidelines, and a centralized database is expected to enhance the effectiveness of NHS. Further research is needed to evaluate these improvements.
Displayed: 28/10/2024 19:00